AXDX - アクセレレ―ト・ダイアグノスティックス (Accelerate Diagnostics Inc.) アクセレレ―ト・ダイアグノスティックス

 AXDXのチャート


 AXDXの企業情報

symbol AXDx
会社名 Accelerate Diagnostics Inc (アクセレレ―ト・ダイアグノスティックス)
分野(sector) Capital Goods   資本財(工業製品)
産業(industry) Biotechnology: Laboratory Analytical Instruments  
業種 先端医療機器_テクノロジ―   医療関連(Health Care)
概要 事業概要 アクセレレイト・ダイアグノスティクス(Accelerate Diagnostics Inc.)は重大な感染症の診断を通じて患者のアウトカムを開発するソリューションを提供するインビトロ診断会社である。同社のin vitro診断プラットフォームであるAccelerate Phenoシステムは、生細菌または真菌細胞が特定の抗生物質に耐性かまたは感受性かを決定する抗生物質感受性試験(AST)を行うための遺伝子型技術(ID)、感染性病原体および表現型技術を利用する 。同社は単一の患者サンプルから直接病原体を検出・同定し、続いて同定結果に基づいて抗菌剤感受性試験を行う。Accelerate PhenoTest BCキットは、高い罹患率と死亡リスクを伴う生命を脅かす状態である菌血症または真菌血症の疑いのある患者に、IDとASTの結果を提供する。Accelerate Phenoシステムは、ウォークアウェイの自動化を特長とし、固定計測器と一回使用のテストキットで構成される。   アクセレレ―ト・ダイアグノスティックスは米国で医療診断機器を製造、販売。「ID/ASTシステム」の名前で感染性病原体の同定と薬剤感受性試験向け機器、検査キットを提供。敗血症と呼吸器感染などの診断のためにグラム陽性菌とグラム陰性菌の抗生物質への感受性を検査。   Accelerate Diagnostics, Inc. is an in vitro diagnostics company dedicated to providing solutions for the global challenges of antibiotic resistance and sepsis. The Accelerate Pheno® system and Accelerate PhenoTest® BC kit combine several technologies aimed at reducing the time clinicians must wait to determine the most optimal antibiotic therapy for deadly infections. The FDA cleared system and kit fully automate the sample preparation steps to report phenotypic antibiotic susceptibility results in approximately 7 hours direct from positive blood cultures. Recent external studies indicate the solution offers results 1-2 days faster than existing methods, enabling clinicians to optimize antibiotic selection and dosage specific to the individual patient days earlier.
本社所在地 3950 South Country Club Road Suite 470 Tucson AZ 85714 USA
代表者氏名 John Patience ジョン・ペイシェンス
代表者役職名 Independent Chairman of the Board
電話番号 +1 303-863-8088
設立年月日 30072
市場名 NASDAQ Small Cap
ipoyear ―年
従業員数 239人
url www.acceleratediagnostics.com
nasdaq_url https://www.nasdaq.com/symbol/axdx
adr_tso
EBITDA EBITDA(百万ドル) -72.46400
終値(lastsale) 18.4197
時価総額(marketcap) 997021337.403
時価総額 時価総額(百万ドル) 974.57450
売上高 売上高(百万ドル) 5.44000
企業価値(EV) 企業価値(EV)(百万ドル) 892.66950
当期純利益 当期純利益(百万ドル) -77.40700
決算概要 決算概要 BRIEF: For the six months ended 30 June 2018 Accelerate Diagnostics Inc revenues increased from $1.2M to $2.5M. Net loss increased 44% to $44M. Revenues reflect Domestic(United States) segment increase of 71% to $1.8M Foreign-World ex-United States (Region) segment increase from $167K to $678K. Higher net loss reflects Other Sales general and administrative increase of 48% to $23.2M (expense).

 AXDXのテクニカル分析


 AXDXのニュース

   Accelerate Diagnostics Inc Shares Near 52-Week Low - Market Mover  2021/07/17 22:21:27 Kwhen Finance
Accelerate Diagnostics Inc (AXDX) shares closed today at 1.4% above its 52 week low of $6.44, giving the company a market cap of $398M. The stock is currently down 13.9% year-to-date, down 63.8% over the past 12 months, and down 66.8% over the past five years. This week, the Dow Jones Industrial Average fell 0.5%, and the S&P 500 fell 1.0%. Trading Activity Trading volume this week was 10.1% lower than the 20-day average.Beta, a measure of the stocks volatility relative to the overall market stands at 0.6. Technical Indicators The Relative Strength Index (RSI) on the stock was under 30, indicating it may be underbought.MACD, a trend-following momentum indicator, indicates a downward trend.The stock closed below its Bollinger band, indicating it may be oversold.The stock closed at 3.3% lower than its 5-day moving average, 15.6% lower than its 20-day moving average, and 18.5% lower than its 90-day moving average. Market Comparative Performance The company's share price is the same as the S&P 500 Index , lags it on a 1-year basis, and lags it on a 5-year basis The company's share price is the same as the Dow Jones Industrial Average , lags it on a 1-year basis, and lags it on a 5-year basis The company share price is the same as the performance of its peers in the Health Care industry sector , lags it on a 1-year basis, and lags it on a 5 year basis Per Group Comparative Performance The company's stock price performance year-to-date lags the peer average by -226.1% The company's stock price performance over the past 12 months lags the peer average by -253.2% This story was produced by the Kwhen Automated News Generator. For more articles like this, please visit us at finance.kwhen.com. Write to editors@kwhen.com. © 2020 Kwhen Inc.
   Antimicrobial Susceptibility Testing Market Prominent Players Analysis: Bruker (US), Roche Diagnostics Limited (Switzerland), Accelerate Diagnostics, Inc. (US)  2021/07/15 18:08:15 Tramways Monthly
The antimicrobial susceptibility testing market is projected to reach USD 4.2 billion by 2025 from USD 3.2 billion in 2020, at a CAGR of 5.5% during the forecast period. Growth of the market is mainly attributed to the technological advancements; increasing incidences of infectious diseases, and growing public and private investments, funding, and grants are []
   Up 6% in June, Is Accelerate Diagnostics a Good Buy Now?  2021/07/08 10:31:00 The Motley Fool
Investors were encouraged by a recent award the company received in the effort to diagnose and treat sepsis more rapidly.
   Accelerate Diagnostics Launches a Fast Antimicrobial Susceptibility Test for Use with Existing ID Systems in the United States  2021/07/07 12:00:00 PR Newswire
TUCSON, Ariz., July 7, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) today announced the launch of a new IVD configuration of its Accelerate PhenoTest® BC kit in the United States. With this launch, the Company now provides two solutions for fast sepsis testing. The new
   New Accelerate Pheno® Landmark Study Validates Important Clinical Benefits to Be Presented at ECCMID 2021  2021/06/30 14:05:00 Benzinga
TUCSON, Ariz. , June 30, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX ) today announced that it will have 3 data presentations from its Improving Outcomes and Antibiotic Stewardship (IOAS) Study at the European Congress of Clinical Microbiology & Infectious Diseases (ECCMID) to be held July 912, 2021. The purpose of this landmark study is to compare data before and after implementation of the Accelerate Pheno system across several hospitals to determine the effects of the system on treating patients with bloodstream infections. The ePoster presentations are from real-world clinical use of the Accelerate Pheno system in diverse health systems and include endpoints for microbiology test turnaround time, antimicrobial use, and a subgroup analysis that measured 30-day mortality. The data further highlight the clinical benefits of using the Accelerate Pheno system, Full story available on Benzinga.com
   Accelerate Diagnostics Reports Fourth Quarter and Full-Year 2020 Financial Results  2021/02/23 21:15:00 PR Newswire
TUCSON, Ariz., Feb. 23, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the fourth quarter and full year ended December 31, 2020. "We were pleased with the improvement in our go-live execution over the course of 2020, which drove a…
   Accelerate Diagnostics to Participate in BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2020, at 4:00 p.m. Eastern Time  2021/02/01 13:00:00 PR Newswire
TUCSON, Ariz., Feb. 1, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) announced today that the company is scheduled to present virtually at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 18, 2020, at 4:00 p.m. Eastern Time. A…
   Accelerate Diagnostics Announces Preliminary Fourth Quarter and Full-Year 2020 Financial Results  2021/01/12 11:00:00 PR Newswire
TUCSON, Ariz., Jan. 12, 2021 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced preliminary financial results for the fourth quarter and full year ending December 31, 2020. Highlights for the fourth quarter and full-year 2020 are presented below. 2020 Fourth…
   Global Bloodstream Infection Testing Market (2020 to 2024) - Featuring Abbott Laboratories, Accelerate Diagnostics and Becton Among Others - ResearchAndMarkets.com  2020/12/07 11:24:00 Business Wire
DUBLIN--(BUSINESS WIRE)--The "Global Bloodstream Infection Testing Market 2020-2024" report has been added to ResearchAndMarkets.com's offering. The publisher has been monitoring the bloodstream infection testing market and it is poised to grow by USD 691.32 million during 2020-2024, progressing at a CAGR of 9% during the forecast period. The reports on the bloodstream infection testing market provide a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well
   Accelerate Diagnostics Reports Third Quarter 2020 Financial Results  2020/11/05 21:29:00 PR Newswire
TUCSON, Ariz., Nov. 5, 2020 /PRNewswire/ -- Accelerate Diagnostics, Inc. (Nasdaq: AXDX) today announced financial results for the third quarter ended September 30, 2020. "We achieved solid revenue growth in the third quarter, driven by continued steady utilization within our installed…

 関連キーワード  (先端医療機器_テクノロジ― 米国株 アクセレレ―ト・ダイアグノスティックス AXDX Accelerate Diagnostics Inc.)

医療で使われる機器のこと。レントゲン装置やからだの断面を画像化できるMRI(磁気共鳴画像)装置など高機能機器を含め数多くの種類がある。医療現場で使われるため、正確で精密である点などが求められる。医療機器への需要は着実に高まっており、電機メーカーなどからの進出も進んでいる。

 twitter  (公式ツイッターやCEOツイッターなど)